PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 trial explores a combination treatment for elderly patients with advanced solid tumors who have limited options. Participants take PRaG-1 Cordycepin tablets, receive targeted radiotherapy, get daily GM-CSF injections, and are treated with PD-1/PD-L1 inhibitors. Immune function and tumor response are monitored through blood tests and tumor biopsies before and after two treatment cycles, with safety assessments throughout.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 65 years.
2. Histologically confirmed treatment-naïve or relapsed/metastatic advanced solid malignancies with no standard treatment option per current clinical guidelines or intolerance to standard therapy; measurable metastatic lesions ≥1 cm (by RECIST criteria); absolute lymphocyte count (ALC) below lower limit of normal (LLN).
3. No history of congestive heart failure, unstable angina, or unstable cardiac arrhythmias within the past 6 months.
4. ECOG performance status 0-3; estimated life expectancy ≥3 months.
5. No history of significant hematologic, cardiac, pulmonary, hepatic, or renal dysfunction.
6. Baseline AST ≤3×ULN and ALT ≤3×ULN (≤5×ULN for hepatocellular carcinoma or liver metastases); creatinine ≤3×ULN.
7. Capacity to comprehend study procedures and voluntarily provide written informed consent.

Exclusion Criteria:

1. History of other malignancies within the past 5 years, except for adequately treated non-melanoma skin cancer or cervical carcinoma in situ.
2. Uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders that, in the investigator's judgment, may interfere with informed consent or treatment adherence.
3. Clinically significant active cardiac disease, including symptomatic coronary artery disease, NYHA Class II or higher congestive heart failure, severe arrhythmias requiring pharmacological intervention, or myocardial infarction within the past 12 months.
4. History of solid organ transplant requiring ongoing immunosuppressive therapy.
5. Known significant active infection, or significant hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction, or other serious uncontrolled comorbidities as determined by the investigator.
6. Allergy to any component of the study drug(s).
7. History of immunodeficiency, including HIV infection, acquired or congenital immunodeficiency disorders, solid organ transplant, or chronic immunosuppressive therapy for immune-related conditions.
8. Active or latent tuberculosis infection confirmed by positive T-SPOT.TB test or chest X-ray findings suggestive of tuberculosis.
9. Any other condition that, in the investigator's clinical judgment, may compromise study participation or safety.

Where it's running

• The Second Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Liyuan Zhang, Doctor
• Email: zhangliyuan126@126.com
• Phone: 051267784829

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Cordycepin (PRaG-1) to raise CD8+ T‑cell counts after treatment for solid tumors

  This trial will test whether PRaG-1 (cordycepin) can raise low CD8+ T‑cell counts in adults who are tumor‑free after treatment for solid cancers.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07258160

• Lattice radiation combined with immunotherapy for advanced solid tumors

  This trial will test whether combining lattice (spatially fractionated) radiation with immunotherapy helps people with advanced or metastatic solid tumors.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07058948

• Multimodal radiotherapy for advanced renal cell carcinoma after immunotherapy

  This study is testing whether combining different types of radiation therapy with ongoing treatment can help people with advanced kidney cancer who haven't responded well to previous immunotherapy.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT06255223

• Assessing safety of combining radiotherapy with new systemic therapies for breast cancer

  This study is testing if it's safe to give new breast cancer treatments together with radiation therapy to see if they can work well together for patients who need both.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06197581

• Induction chemotherapy with low-dose radiation and cadonilimab for locally advanced nasopharyngeal carcinoma

  This study will try adding low-dose radiation and the immune drug cadonilimab to induction chemotherapy before standard concurrent chemoradiotherapy in adults with newly diagnosed locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT05941741

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.